A vancomycin level should be obtained 48 h post-dose. Nine drug-free bags were used as controls. Vancomycin was stable for 4 days at 37°C and for 14 days at both 25°C and 4°C. The mean C On the other hand, datafrom a single-center study involving 34 PD patients experi-used with an average residual creatinine clearance of 2.8above 15 mg/L. Initial presentation and management of peritonitis Clinical pharmacokinetic considerationsPeritoneal transport of vancomycin in 4 patients undergoing continuous ambulatory peritoneal dialysisPharmacokinetics of intraperitoneal and intravenous fosfomycin in automated peritoneal dialysis patients without peritonitisAn open, randomized, single-center, crossover pharmacokinetic study of meropenem after intraperitoneal and intravenous administration in patients receiving automated peritoneal dialysisISPD peritonitis recommendations: 2016 update on prevention and treatmentEvaluation of the pharmacodynamic profile of commonly used intravenous vancomycin dosing schemes in patients on automated peritoneal dialysisPeritoneal dialysis-related infections recommendations: 2010 updateSingle UK Centre experience on the treatment of PD peritonitis--antibiotic levels and outcomesPharmacokinetics of intraperitoneal cefazolin and gentamicin in empiric therapy of peritonitis in continuous ambulatory peritoneal dialysis patientsResidual kidney function and peritoneal dialysis-associated peritonitis treatment outcomesIntraperitoneal vancomycin concentrations during peritoneal dialysis-associated peritonitis: correlation with serum levelsTrough serum vancomycin levels predict the relapse of gram-positive peritonitis in peritoneal dialysis patientsThe role of monitoring vancomycin levels in patients with peritoneal dialysis-associated peritonitisVancomycin pharmacokinetics in patients with peritonitis on peritoneal dialysisOnce weekly intraperitoneal therapy for gram-positive peritonitisVancomycin: the tale of the vanquisher and the pyrrhic victory Peritoneum and dialysate properties should be considered as both theseaffect the rate and the extent of absorption following an intraperitoneal dose. The data were analyzed using generalized estimating equation models to determine the covariate-adjusted association between urinary creatinine clearance and treatment failure (defined as relapse or recurrent peritonitis episodes, peritoneal catheter removal, or death from any cause during peritonitis treatment). Please check you selected the correct society from the list and entered the user name and password you use to log in to your society website.Vancomycin physicochemical properties and drug transport across the peritoneumPeritoneal dialysis-related peritonitis: challenges and solutionsVancomycin: a review of population pharmacokinetic analysesTherapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases PharmacistsPharmacokinetics of vancomycin in patients with various degrees of renal functionThe rationale for revising the clinical and laboratory standards institute vancomycin minimal inhibitory concentration interpretive criteria for staphylococcus aureusRelationship of mic and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant staphylococcus aureus bacteremiaTreatment outcomes for serious infections caused by methicillin-resistant staphylococcus aureus with reduced vancomycin susceptibilityPharmacodynamics of vancomycin and other antimicrobials in patients with staphylococcus aureus lower respiratory tract infectionsStability and compatibility of antibiotics in peritoneal dialysis solutions applied to automated peritoneal dialysis in the pediatric populationStability of antibiotics for intraperitoneal administration in extraneal 7.5% icodextrin peritoneal dialysis bags (stab study)Small and middle molecular weight solute clearance in nocturnal intermittent peritoneal dialysisIntravenous vancomycin pharmacokinetics in automated peritoneal dialysis patientsTeicoplanin pharmacokinetics and bioavailability during peritoneal dialysisComparative study of intraperitoneal and intravenous vancomycin pharmacokinetics during continuous ambulatory peritoneal dialysisVancomycin pharmacokinetics during continuous ambulatory peritoneal dialysis in patients with peritonitisVancomycin disposition following intraperitoneal administration in children receiving peritoneal dialysisVancomycin kinetics during continuous ambulatory peritoneal dialysisPharmacokinetics of once daily intra-peritoneal aztreonam and vancomycin in the treatment of CAPD peritonitisPrediction of serum vancomycin concentrations following intraperitoneal loading doses in continuous ambulatory peritoneal dialysis patients with peritonitisVancomycin administration in continuous ambulatory peritoneal dialysis: the risk of ototoxicityVancomycin disposition during continuous ambulatory peritoneal dialysis: a pharmacokinetic analysis of peritoneal drug transportClearance from dialysate and equilibration of intraperitoneal vancomycin in continuous ambulatory peritoneal dialysisPharmacokinetics of vancomycin in patients undergoing continuous ambulatory peritoneal dialysisVancomycin pharmacokinetics in continuous ambulatory peritoneal dialysis patients with peritonitisPharmacokinetics of single dose intravenous vancomycin in CAPD peritonitisVancomycin removal during high-volume peritoneal dialysis in acute kidney injury patientsDrug therapy in patients undergoing peritoneal dialysis.